⚠ Evidence warning: Clinical trials or other evidence do not support the claim that spiramycin reduces the rate of maternal-to-fetal transmission by about 60%. This page keeps it as a report of what people, websites or other media say.
Toxoplasmosis
Table of Contents
Overview
Toxoplasmosis is an infection caused by Toxoplasma gondii, an obligate intracellular protozoan parasite that infects virtually all warm-blooded animals. It holds the distinction of being the most common protozoan infection globally as measured by seroprevalence, with an estimated one-third of the world’s population carrying latent infection.
The parasite has a complex two-host life cycle. Cats and other felids are the only definitive hosts — meaning the sexual stage of the parasite’s reproduction occurs exclusively in their intestinal epithelium, producing oocysts that are shed in feces. A single acutely infected cat can shed hundreds of millions of oocysts over a two-week window; those oocysts sporulate in the environment within 1–5 days and remain infectious in warm moist soil for up to 18 months.
Humans acquire infection through three primary routes:
- Ingestion of oocysts from cat-feces-contaminated soil, water, or unwashed produce
- Ingestion of tissue cysts (bradyzoites) in undercooked or raw meat — lamb, pork, and venison carry the highest cyst burdens
- Transplacental transmission when a pregnant woman acquires primary infection
In healthy adults, toxoplasmosis is almost always silent or causes only a mild, self-limited illness resembling mononucleosis. The danger arises in two groups: immunocompromised patients (particularly those with acquired immunodeficiency syndrome (AIDS) and CD4 counts below 100 cells/μL), in whom latent cysts can reactivate to cause life-threatening encephalitis; and fetuses infected in utero, who face risks of chorioretinitis, hydrocephalus, and severe developmental impairment.
Seroprevalence in the United States is approximately 10–15% of the general population, but in Brazil and much of sub-Saharan Africa it exceeds 50–80%, and in France it stood at 55.0% of pregnant women in 1995 and 33.7% in 2016, reflecting differences in meat-eating habits, cat density, climate, and sanitation.
Epidemiology
Toxoplasma gondii infects an estimated 30% of the global human population, making it one of the most successful parasitic infections in history. Geographic distribution is worldwide, but seroprevalence is strikingly unequal.
High-prevalence regions include France (age-standardised 55.0% of pregnant women in 1995, falling to 33.7% in 2016, per the French national perinatal survey), Brazil (up to 78% in some studies), Ethiopia, Turkey, and parts of Southeast Asia and Latin America. Low-prevalence regions include northern Europe, North America, and Southeast Asia outside of continental areas. The United States has seen seroprevalence fall over decades, possibly reflecting changed meat-handling practices and indoor cat ownership. The national survey (NHANES) found an age-adjusted 22.5% in 1988–1994 among people aged 12 and over, and 13.2% overall (12.4% age-adjusted) in 2009–2010 among people aged 6 and over; those two figures cover different age groups. Compared like for like, US-born people aged 12–49 went from 14.1% in 1988–1994 to 9.0% in 1999–2004 to 6.7% in 2009–2010.
Key risk factors in the US and Europe:
- Eating undercooked or raw meat (lamb, pork, game) — the dominant transmission route in high-income countries
- Gardening without gloves in soil contaminated by cat feces
- Changing cat litter boxes, especially with outdoor cats
- Travel to highly endemic areas
- Drinking unfiltered surface water (oocysts resist standard chlorination)
- Receiving organ transplants from seropositive donors (T. gondii seropositive donor + seronegative recipient = highest risk)
Congenital toxoplasmosis occurs when a woman who has never been infected acquires primary T. gondii infection during pregnancy and the parasite crosses the placenta. Approximately 4,000 cases of congenital toxoplasmosis occur annually in the United States, and the economic burden of lifetime care for affected children exceeds $750 million per year. First-trimester infection carries a lower transmission rate (~15%) but causes the most severe fetal damage; third-trimester infection transmits more frequently (~60–65%) but usually causes subclinical disease at birth, with late-onset eye and neurological problems emerging months to years later.
Immunocompromised populations are at risk of life-threatening reactivation. Before modern antiretroviral therapy, toxoplasmic encephalitis was the most common cause of focal brain lesions in acquired immunodeficiency syndrome patients, accounting for 50–60% of such cases. The risk is highest when CD4 falls below 100 cells/μL in a Toxoplasma immunoglobulin G-positive patient who is not on prophylaxis.
Pathophysiology
Understanding how T. gondii causes disease requires following its journey through three distinct parasite forms: oocysts (shed in cat feces), tachyzoites (the fast-replicating acute form), and bradyzoites (the slow-replicating cyst form that persists in tissue for life).
Entry and transformation. After a human ingests oocysts from contaminated food or soil, stomach acid and pancreatic enzymes degrade the oocyst wall, releasing sporozoites. These penetrate intestinal epithelial cells and transform into tachyzoites, the rapidly dividing asexual form. Similarly, if tissue cysts in undercooked meat are ingested, the low pH of the stomach disrupts the cyst wall, releasing bradyzoites that convert to tachyzoites in the intestinal mucosa.
Hematogenous dissemination. Tachyzoites infect macrophages and dendritic cells in the intestinal lamina propria. Rather than being destroyed, they hijack these professional phagocytes to hitch a ride through the bloodstream and lymphatics — a Trojan horse strategy that allows dissemination to the brain, retina, skeletal muscle, and myocardium.
Parasite immune evasion. T. gondii is a master of intracellular immune evasion. It resides within a specialized vacuole called the parasitophorous vacuole membrane (PVM) that it constructs as it enters the cell. The PVM:
- Intercepts and recruits host mitochondria and endoplasmic reticulum to its surface for nutrient acquisition
- Prevents fusion with lysosomes, blocking degradation
- Inhibits phagosome acidification
- Suppresses host cell apoptosis, keeping its replicative niche alive
- Downregulates MHC class II expression, reducing antigen presentation
Cyst formation and latency. Immune pressure — primarily from IFN-γ produced by natural killer (NK) cells and T lymphocytes — forces tachyzoites to convert into bradyzoites, which build a thick-walled tissue cyst. Cysts are most common in neurons and skeletal muscle cells. They can contain hundreds to thousands of bradyzoites and remain dormant in immunocompetent hosts for the lifetime of the individual without causing symptoms. Immunoglobulin G (IgG) antibodies persist lifelong as a marker of this latent infection.
Reactivation in immunosuppression. When T-cell-mediated immunity fails — as in untreated human immunodeficiency virus (HIV) infection, immunosuppressive therapy after organ transplant, or lymphoma — bradyzoites convert back to tachyzoites. In the brain, this produces toxoplasmic encephalitis: rapidly expanding foci of necrosis surrounded by inflammatory infiltrate, classically appearing as multiple ring-enhancing lesions on magnetic resonance imaging (MRI). Without treatment, progressive cerebral destruction is fatal.
Congenital disease mechanism. Tachyzoites in the maternal bloodstream can cross the placental barrier. The fetal immune system, which is tolerogenic by design, cannot mount effective T-cell responses against the parasite. Tachyzoites replicate unchecked, destroying developing neural tissue and the retina.
Clinical Presentation
The clinical picture of toxoplasmosis varies dramatically depending on the host’s immune status and whether infection is acquired, reactivated, congenital, or ocular.
Immunocompetent Adults
Approximately 80–90% of primary infections in healthy adults are completely asymptomatic. The remaining 10–20% develop a self-limited illness that closely mimics infectious mononucleosis:
- Cervical or axillary lymphadenopathy — the single most common finding; nodes are tender, non-suppurative, and may persist for months
- Low-grade fever and fatigue, often lasting 2–6 weeks
- Headache, myalgias, and night sweats
- Heterophile antibody test (monospot) is negative — helping distinguish it from Epstein-Barr virus (EBV) mononucleosis
Rare complications in otherwise healthy people include pneumonitis, myocarditis, polymyositis, and hepatitis. These are more common in primary infections acquired in immunocompetent adults in endemic areas.
Toxoplasmic Encephalitis (Immunocompromised)
Reactivation in acquired immunodeficiency syndrome (CD4 <100 cells/μL) or transplant recipients produces toxoplasmic encephalitis (TE), the most devastating form of the disease. Onset is subacute over days to weeks:
- Headache (75%), fever (60–70%), and focal neurological deficits (60%) — hemiparesis, aphasia, hemianopia, or cerebellar ataxia depending on lesion location
- Confusion, somnolence, and behavioral changes
- Seizures in 25–30% of patients
- Meningismus is uncommon — an important distinguishing feature from bacterial meningitis
Brain imaging is essential. Magnetic resonance imaging is more sensitive than computed tomography (CT). The classic finding is multiple ring-enhancing lesions at the gray-white junction and in the basal ganglia and thalami. The “eccentric target sign” on magnetic resonance imaging (a small eccentric nodule within the ring of enhancement) is highly specific for toxoplasmosis. Mass effect and surrounding edema are common. A single lesion, or a lesion in the corpus callosum, raises suspicion for primary central nervous system (CNS) lymphoma instead. Because brain biopsy carries risks, empiric treatment with anti-Toxoplasma drugs is standard; clinical and radiological improvement within 2 weeks is considered diagnostic.
Congenital Toxoplasmosis
The classic triad of congenital toxoplasmosis taught in medical school is:
- Chorioretinitis (most common finding, affects 75–80% of symptomatic neonates)
- Hydrocephalus
- Intracranial calcifications
However, up to 75% of infected newborns appear normal at birth. Late sequelae — emerging months to years later — include retinochoroiditis, sensorineural hearing loss, cognitive impairment, and epilepsy. First-trimester infections, while less frequent, cause the most severe outcomes: spontaneous abortion, stillbirth, or extensive brain destruction. Gestational age at infection is the single strongest predictor of severity.
Ocular Toxoplasmosis
Toxoplasmosis is the most common cause of infectious posterior uveitis worldwide. It can result from congenital infection (reactivating years later) or acquired infection. The hallmark is a focal area of active retinal necrosis adjacent to an old chorioretinal scar — described as a “headlight in the fog” (white fluffy active lesion adjacent to a pigmented scar). Symptoms include blurred vision, floaters, photophobia, and scotoma. Recurrences are common, and each episode can enlarge the scar and threaten vision — particularly when lesions encroach on the macula or optic disc.
Diagnosis
Diagnosing toxoplasmosis requires integrating serological results, clinical context, imaging, and sometimes direct parasite detection. No single test is definitive in all settings.
Serology
Immunoglobulin G and immunoglobulin M (IgM) antibodies are the foundation of diagnosis. Immunoglobulin M appears within 1–2 weeks of infection, peaks within a month, and typically declines over 6–9 months — but can persist for up to 18 months, limiting its utility in distinguishing recent from past infection. Immunoglobulin G appears slightly later, reaches peak titers at 1–2 months, and persists for life.
The immunoglobulin G avidity test resolves the “immunoglobulin M still positive” problem: low immunoglobulin G avidity indicates infection within the past 3–5 months; high avidity effectively rules out recent infection. This is especially important in pregnancy — a high-avidity result in the first trimester means infection predated conception and the fetus is likely not at risk.
In immunocompromised patients, serology can be misleading: anti-Toxoplasma immunoglobulin G is typically positive (confirming prior infection and reactivation risk), but immunoglobulin M and rising immunoglobulin G titers may be absent due to the failure to mount a humoral response. A positive Toxoplasma immunoglobulin G in a human immunodeficiency virus patient with CD4 <100 is sufficient to establish reactivation risk without further serological workup.
Neuroimaging
Magnetic resonance imaging with gadolinium is the imaging study of choice for suspected toxoplasmic encephalitis. It is more sensitive than computed tomography, revealing lesions missed by computed tomography in up to 15% of cases. Classic findings: multiple ring-enhancing lesions (usually >1 cm) with surrounding edema, bilateral, preferentially in the basal ganglia and frontal-parietal junction. The eccentric target sign (an off-center enhancing core within the ring on post-contrast T1-weighted images) is considered pathognomonic of toxoplasmosis (Kumar 2010). A separate sign on T2-weighted images, the concentric target sign (alternating dark and bright rings), is believed to be more specific than the eccentric sign, though how exclusive it is to toxoplasmosis remains to be worked out (Mahadevan 2013). A specificity of 71–72% is also quoted for a target sign; neither of these two papers gives that figure. A single lesion strongly suggests primary central nervous system lymphoma, especially in an Epstein-Barr virus-positive patient.
Cerebrospinal Fluid Analysis and Polymerase Chain Reaction
Lumbar puncture findings in TE are non-specific: mild lymphocytic pleocytosis and elevated protein in about half of cases. Cerebrospinal fluid (CSF) polymerase chain reaction (PCR) for T. gondii has a sensitivity of only 50–60% in TE but is highly specific (>95%). A positive cerebrospinal fluid polymerase chain reaction confirms the diagnosis; a negative result does not exclude it. Polymerase chain reaction is more useful in amniotic fluid for confirming fetal infection (sensitivity 64–92% when performed after 18 weeks gestation).
Brain Biopsy
Stereotactic brain biopsy is the gold standard when empiric therapy fails or the diagnosis is uncertain. Histology shows tachyzoites and/or bradyzoites within tissue cysts in a background of inflammatory necrosis. Immunohistochemistry enhances sensitivity. Biopsy is generally reserved for patients who deteriorate on empiric therapy after 2 weeks.
Neonatal and Congenital Screening
In the US, universal newborn screening for congenital toxoplasmosis is performed in Massachusetts and New Hampshire using neonatal blood spot immunoglobulin M and immunoglobulin A (IgA) assays. Ophthalmologic examination is mandatory for all confirmed cases. Confirmatory testing at a reference laboratory (National Reference Laboratory for Toxoplasmosis) uses multi-test serological panels.
Treatment
Treatment decisions in toxoplasmosis depend on which form of disease is present, the patient’s immune status, and pregnancy status. The cornerstone agents are pyrimethamine (a dihydrofolate reductase inhibitor) and sulfadiazine (a sulfonamide), which act synergistically against tachyzoites. Neither drug reliably kills bradyzoites in tissue cysts, which is why immunocompromised patients require lifelong suppressive therapy.
Toxoplasmic Encephalitis in Immunocompromised Patients
First-line acute treatment (6 weeks minimum):
- Pyrimethamine 200 mg orally as a loading dose, then 50 mg/day (<60 kg) or 75 mg/day (≥60 kg)
- Sulfadiazine 1,000–1,500 mg orally four times daily
- Leucovorin (folinic acid) 10–25 mg/day orally — used to prevent pyrimethamine-induced bone marrow suppression, and continued for 1 week after pyrimethamine is stopped
Alternative for sulfa allergy: Pyrimethamine + Clindamycin 600 mg every 6 hours (comparable efficacy in trials; diarrhea is the main side effect). Other alternatives with limited data include pyrimethamine + atovaquone, or trimethoprim-sulfamethoxazole (TMP-SMX) alone for mild immunosuppression.
Maintenance Therapy (Secondary Prophylaxis)
After acute treatment, immunocompromised patients receive indefinite suppressive therapy to prevent relapse:
- Pyrimethamine 25–50 mg/day + Sulfadiazine 2,000–4,000 mg/day (divided doses) + Leucovorin
- In human immunodeficiency virus, guidelines list stopping when CD4 >200 cells/μL for ≥6 months on effective antiretroviral therapy (ART)
- The same guidelines list restarting if CD4 falls below 200 again
Primary Prophylaxis in Human Immunodeficiency Virus
US guidelines from the Centers for Disease Control and Prevention, the National Institutes of Health and the HIV Medicine Association (2009 edition listed below; later editions update it) list primary prophylaxis to prevent a first episode of TE for human immunodeficiency virus-positive patients with CD4 <100 cells/μL who are Toxoplasma immunoglobulin G-positive: trimethoprim-sulfamethoxazole 1 double-strength tablet daily. This is the same regimen used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, so coverage is achieved with one pill. The guidelines list stopping when CD4 >200 for ≥3 months.
Immunocompetent Patients
Most healthy adults with symptomatic primary toxoplasmosis do not require treatment — the illness is self-limited. Treatment is considered for:
- Severe or persistent symptoms (>4 weeks)
- Patients with organ damage (pneumonitis, myocarditis)
Regimen: Pyrimethamine + Sulfadiazine + Leucovorin for 4–6 weeks. Immunocompromised patients with any form of the disease are treated too, as described above.
Congenital Toxoplasmosis
All infants with confirmed congenital toxoplasmosis receive treatment for 12 months regardless of whether they appear symptomatic at birth, because subclinical disease at birth does not reliably predict the absence of long-term sequelae. Standard regimen: Pyrimethamine + Sulfadiazine + Leucovorin for 12 months (with monthly complete blood count (CBC) monitoring for pyrimethamine toxicity). Prednisone is added when cerebrospinal fluid protein is ≥1 g/dL or active chorioretinitis threatens vision.
Toxoplasmosis in Pregnancy
Management depends on gestational age and whether fetal infection is confirmed:
- Before 18 weeks, fetal infection not confirmed: Spiramycin 1 g every 8 hours (a macrolide antibiotic not teratogenic in the first trimester). Spiramycin concentrates in placental tissue and does NOT treat an already-infected fetus. A reduction of about 60% in maternal-to-fetal transmission is often repeated for it, but the studies listed below do not report that figure: Foulon 1999 found prenatal antibiotics had no impact on the transmission rate, and the SYROCOT pooled analysis found only weak evidence that treatment started within 3 weeks of infection lowered transmission compared with treatment started after 8 weeks or more (adjusted odds ratio 0.48).
- After 18 weeks or confirmed fetal infection by amniocentesis polymerase chain reaction: Switch to Pyrimethamine + Sulfadiazine + Leucovorin. Pyrimethamine is teratogenic in the first trimester (folate antagonist), and this schedule does not use it before 18 weeks.
What the pregnancy trials report. The only randomized trial comparing the two prenatal regimens (143 women in France) found mother-to-child transmission in 18.5% (12 of 65) with pyrimethamine plus sulfadiazine and 30% (18 of 60) with spiramycin. That difference did not reach statistical significance, and the trial stopped enrolling early, so it may have been too small to show one. Brain abnormalities on fetal ultrasound appeared in 0 of 73 fetuses versus 6 of 70. Two women had severe rashes, both on pyrimethamine plus sulfadiazine. In an earlier multicenter study of 144 women infected during pregnancy, antibiotics did not change how often the parasite reached the baby, but infected children had fewer lasting problems at age 1 (odds ratio 0.30), and the sooner treatment began the fewer problems were seen. A later pooled analysis of 550 infected infants found no evidence that prenatal treatment significantly reduced clinical signs (adjusted odds ratio 1.11), so the benefit remains disputed; its authors say only a large randomized trial would settle it.
Note: Spiramycin is not U.S. Food and Drug Administration-approved in the United States and must be obtained through the U.S. Food and Drug Administration (FDA) under an IND (Investigational New Drug) protocol.
Ocular Toxoplasmosis
Vision-threatening lesions (posterior pole, threatening macula or optic disc) require treatment: Pyrimethamine + Sulfadiazine + Leucovorin, with oral prednisone added 24–48 hours after starting anti-parasitic therapy to control the inflammatory response. Duration: 4–6 weeks, with ophthalmology follow-up. Peripheral lesions in immunocompetent patients may be observed without treatment. Long-term intermittent prophylaxis (trimethoprim-sulfamethoxazole 3 days/week) is an option described for patients with frequent recurrences. In a double-masked trial of 141 people in Brazil with recurrent eye toxoplasmosis, one year of trimethoprim-sulfamethoxazole every other day, after initial treatment, was followed by recurrence in 1.4% (1 of 72) at 6 years, against 27.5% (19 of 69) on placebo, with no treatment-limiting side effects reported.
Complications
The complications of toxoplasmosis range from mild and reversible to permanently disabling or fatal, depending largely on immune status and the organ system involved.
Central nervous system. Toxoplasmic encephalitis left untreated in acquired immunodeficiency syndrome patients is universally fatal. Even with treatment, survivors may be left with permanent neurological deficits: focal weakness, aphasia, cognitive impairment, epilepsy, or vision loss from optic nerve involvement. Hydrocephalus requiring shunting develops in a minority of cases. In transplant recipients, TE carries mortality of 50–70% even with treatment, reflecting the depth of iatrogenic immunosuppression.
Immune reconstitution inflammatory syndrome (IRIS). When ART is initiated in an acquired immunodeficiency syndrome patient with occult or partially treated TE, rapid recovery of T-cell function can trigger paradoxical worsening — IRIS. Cerebral IRIS presents as new or enlarging ring-enhancing lesions, headache, and fever in the context of falling viral load and rising CD4 count. Management includes continuing ART plus corticosteroids.
Treatment toxicity. The standard pyrimethamine + sulfadiazine regimen has significant side effects: bone marrow suppression (neutropenia, thrombocytopenia, anemia) from pyrimethamine’s folate antagonism, which is mitigated but not eliminated by leucovorin; Stevens-Johnson syndrome and toxic epidermal necrolysis from sulfadiazine (<1% but potentially fatal); nephrotoxicity from sulfadiazine crystalluria (adequate hydration and urine alkalinization are the preventive steps described); and rash, nausea, and vomiting.
Ocular complications. Each episode of ocular reactivation can expand the chorioretinal scar. Lesions near the macula cause permanent central scotoma and legal blindness. Extensive bilateral disease can cause total blindness. Retinal detachment is a rare but devastating complication of large lesions.
Congenital long-term outcomes. Children with symptomatic congenital toxoplasmosis face severe developmental delay, cerebral palsy, epilepsy refractory to treatment, cortical blindness, and profound sensorineural hearing loss. Those treated for 12 months have significantly better cognitive and visual outcomes than untreated historical cohorts, but long-term surveillance is required because chorioretinitis can recur through adolescence and adulthood even in treated individuals.
Prevention
Because most human infections come from two sources — undercooked meat and cat-feces-contaminated soil — prevention is practical and evidence-based. Most cases in the US are preventable.
Food Safety
- Safe internal cooking temperatures listed for meat: 160°F (71°C) for ground meat; 145°F with a 3-minute rest for whole cuts of lamb, pork, and beef; 165°F for poultry, as read on a meat thermometer.
- Freezing meat at −20°C (−4°F) for at least 48 hours kills tissue cysts effectively. Standard home freezers (−18°C) require longer times.
- Soap and hot water on hands, cutting boards, knives, and countertops after contact with raw meat is the listed kitchen step.
- Thorough washing of fruits and vegetables before eating is listed, especially for produce that may have been grown in soil fertilized with cat feces.
- Untreated surface water in endemic areas is a reported source of infection — oocysts resist standard chlorination and require filtration (<1 μm).
Cat-Related Precautions
- Pregnant women and immunocompromised individuals are the groups for whom cleaning cat litter boxes is named as a hazard. Where no alternative exists, the steps listed are disposable gloves and thorough handwashing afterward.
- Cat litter changed daily is removed before it turns infectious — oocysts require 1–5 days to sporulate, so daily removal prevents environmental contamination.
- Indoor cats fed only commercial dry or canned food or thoroughly cooked meat have less exposure. Cats that hunt rodents or birds are at risk of ingesting tissue cysts and shedding oocysts.
- Gloves for gardening with handwashing afterward are the listed steps for soil. Covered sandboxes keep cats from defecating in them when not in use.
Medical Prophylaxis in High-Risk Patients
- Human immunodeficiency virus patients with CD4 <100 and positive Toxoplasma immunoglobulin G: guidelines list trimethoprim-sulfamethoxazole 1 double-strength tablet daily (also covers PJP), continued until CD4 >200 for ≥3 months on antiretroviral therapy.
- Seronegative transplant recipients from seropositive donors: trimethoprim-sulfamethoxazole for the first 6 months post-transplant, longer in those on high-dose immunosuppression.
- Solid organ transplant recipients: Pyrimethamine + leucovorin for 6 weeks post-transplant if donor is immunoglobulin G-positive and recipient is immunoglobulin G-negative.
Blood Product Safety
Transfusion-transmitted toxoplasmosis is rare but documented in granulocyte transfusion recipients. The concern is seropositive blood products given to seronegative immunocompromised recipients, and matching is described where possible. Leukoreduction reduces (but does not eliminate) risk.
Research and Advances
Toxoplasma research has accelerated since the 1990s, driven both by the acquired immunodeficiency syndrome epidemic and by the parasite’s extraordinary utility as a model intracellular pathogen. Several areas hold particular promise for patients and public health.
Behavioral manipulation hypothesis. One of the most intriguing areas of toxoplasmosis research is whether latent T. gondii infection alters human behavior. Epidemiological studies have associated Toxoplasma seropositivity with personality trait shifts (slightly higher novelty-seeking and risk-taking in men), slower reaction times, and — controversially — increased incidence of schizophrenia. The proposed mechanism involves parasite-induced upregulation of dopamine biosynthesis in neurons. The data are correlational and confounded; no causation has been established. A 2026 Mendelian randomization study (a genetic analysis, in European populations) did not support a causal link between infection and schizophrenia, bipolar disorder, addiction, obsessive-compulsive disorder or risk-taking; it put any true effect as likely small (odds ratio below 1.18 for schizophrenia and below 1.29 for bipolar disorder), though small or phase-specific effects cannot be excluded. The topic remains scientifically active and provocative.
Anti-bradyzoite agents. Current drugs (pyrimethamine, sulfadiazine) are highly effective against tachyzoites but do not kill bradyzoites in tissue cysts, which is why lifelong secondary prophylaxis is needed in immunocompromised patients. Atovaquone, a mitochondrial electron-transport inhibitor, shows anti-bradyzoite activity in vitro and in murine models. Combination strategies with endochin-like quinolones (ELQs) that inhibit the Toxoplasma mitochondrial cytochrome bc1 complex are under investigation and could one day allow true sterilizing cure of latent infection.
Calcium-dependent protein kinases (CDPKs). T. gondii CDPKs are attractive drug targets because they are essential for parasite motility, invasion, and egress from host cells, and have no close mammalian homologs (humans lack the plant-like EF-hand calcium-binding domain found in parasite CDPKs). High-throughput screening has identified bumped kinase inhibitors (BKIs) — adenosine triphosphate-competitive compounds with a bulky substituent that exploits the unique glycine gatekeeper residue in Toxoplasma CDPKs. BKIs are in preclinical development.
Rapid field diagnostics. Loop-mediated isothermal amplification (LAMP) assays for T. gondii DNA amplify target sequences at a single temperature (65°C) within 60 minutes with sensitivity approaching polymerase chain reaction. Point-of-care LAMP strips readable by eye could enable prenatal screening and field diagnosis in low-resource settings where laboratory infrastructure is limited.
Vaccine development. No human vaccine exists for toxoplasmosis. A live veterinary vaccine made of S48-strain tachyzoites protects sheep from abortion caused by toxoplasmosis. Research is ongoing into live-attenuated and subunit vaccine approaches using surface antigens (SAG1/p30, SAG2) and secreted proteins (GRA, ROP). A fully effective human vaccine would dramatically reduce congenital toxoplasmosis in endemic regions.
Key Research Papers
- Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–1976. DOI: 10.1016/S0140-6736(04)16412-X. — PubMed PMID: 15194258 · doi:10.1016/S0140-6736(04)16412-X
- Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–296. DOI: 10.1128/CMR.05013-11. — PubMed PMID: 22491772 · doi:10.1128/CMR.05013-11
- Bhopale GM. Pathogenesis of toxoplasmosis. Comp Immunol Microbiol Infect Dis. 2003;26(4):213–222. DOI: 10.1016/S0147-9571(02)00058-9. — PubMed PMID: 12676122 · doi:10.1016/S0147-9571(02)00058-9
- Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643–1648. DOI: 10.1056/NEJM199212033272306. — PubMed PMID: 1359410 · doi:10.1056/NEJM199212033272306
- Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993;329(14):995–1000. DOI: 10.1056/NEJM199309303291403. — PubMed PMID: 8366923 · doi:10.1056/NEJM199309303291403
- Jones JL, Kruszon-Moran D, Rivera HN, et al. Toxoplasma gondii seroprevalence in the United States 2009–2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135–1139. DOI: 10.4269/ajtmh.14-0013. — PubMed PMID: 24710615 · doi:10.4269/ajtmh.14-0013
- Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385–1394. DOI: 10.1016/j.ijpara.2009.04.003. — PubMed PMID: 19433092 · doi:10.1016/j.ijpara.2009.04.003
- Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR-4):1–207. — PubMed PMID: 19357635
- Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol. 1999;180(2):410–415. DOI: 10.1016/S0002-9378(99)70224-3. — PubMed PMID: 9988811 · doi:10.1016/S0002-9378(99)70224-3
- Maenz M, Schlüter D, Liesenfeld O, et al. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77–106. DOI: 10.1016/j.preteyeres.2013.12.005. — PubMed PMID: 24412517 · doi:10.1016/j.preteyeres.2013.12.005
- Dabritz HA, Conrad PA. Cats and Toxoplasma: implications for public health. Zoonoses Public Health. 2010;57(1):34–52. DOI: 10.1111/j.1863-2378.2009.01273.x. — PubMed PMID: 19744306 · doi:10.1111/j.1863-2378.2009.01273.x
- Pleyer U, Gross U, Schlüter D, et al. Toxoplasmosis in Germany. Dtsch Arztebl Int. 2019;116(25):435–444. DOI: 10.3238/arztebl.2019.0435. — PubMed PMID: 31423982 · doi:10.3238/arztebl.2019.0435
- Jones JL, Kruszon-Moran D, Wilson M, et al. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol. 2001;154(4):357–365. DOI: 10.1093/aje/154.4.357. — PubMed PMID: 11495859 · doi:10.1093/aje/154.4.357
- Robinson E, de Valk H, Villena I, et al. National perinatal survey demonstrates a decreasing seroprevalence of Toxoplasma gondii infection among pregnant women in France, 1995 to 2016: impact for screening policy. Euro Surveill. 2021;26(5):1900710. DOI: 10.2807/1560-7917.ES.2021.26.5.1900710. — PubMed PMID: 33541484 · doi:10.2807/1560-7917.ES.2021.26.5.1900710
- SYROCOT study group, Thiébaut R, Leproust S, et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. Lancet. 2007;369(9556):115–122. DOI: 10.1016/S0140-6736(07)60072-5. — PubMed PMID: 17223474 · doi:10.1016/S0140-6736(07)60072-5
- Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.e1–386.e9. DOI: 10.1016/j.ajog.2018.05.031. — PubMed PMID: 29870736 · doi:10.1016/j.ajog.2018.05.031
- Fernandes Felix JP, Cavalcanti Lira RP, Grupenmacher AT, et al. Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent Toxoplasma gondii retinochoroiditis. Am J Ophthalmol. 2020;213:195–202. DOI: 10.1016/j.ajo.2019.12.025. — PubMed PMID: 31926883 · doi:10.1016/j.ajo.2019.12.025
- Kumar GG, Mahadevan A, Guruprasad AS, et al. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging. 2010;31(6):1469–1472. DOI: 10.1002/jmri.22192. — PubMed PMID: 20512900 · doi:10.1002/jmri.22192
- Mahadevan A, Ramalingaiah AH, Parthasarathy S, et al. Neuropathological correlate of the “concentric target sign” in MRI of HIV-associated cerebral toxoplasmosis. J Magn Reson Imaging. 2013;38(2):488–495. DOI: 10.1002/jmri.24036. — PubMed PMID: 23440973 · doi:10.1002/jmri.24036
- Buxton D, Thomson KM, Maley S, et al. Experimental challenge of sheep 18 months after vaccination with a live (S48) Toxoplasma gondii vaccine. Vet Rec. 1993;133(13):310–312. DOI: 10.1136/vr.133.13.310. — PubMed PMID: 8236665 · doi:10.1136/vr.133.13.310
- Pang J, Valente MJ, Kim K, Liu X. Does Toxoplasma gondii infection have a causal impact on human psychopathology? A Mendelian randomization analysis. PLoS Pathog. 2026;22(8):e1014312. DOI: 10.1371/journal.ppat.1014312. — PubMed PMID: 42550877 · doi:10.1371/journal.ppat.1014312
PubMed Topic Searches
Search current literature on PubMed for the latest research on toxoplasmosis:
- Toxoplasmic encephalitis acquired immunodeficiency syndrome treatment
- Congenital toxoplasmosis outcomes treatment
- Toxoplasma gondii seroprevalence epidemiology
- Ocular toxoplasmosis uveitis treatment
- Pyrimethamine sulfadiazine toxoplasmosis
- Toxoplasma gondii behavioral effects humans
- Toxoplasma immunoglobulin G avidity pregnancy diagnosis
- Toxoplasma ring-enhancing lesion magnetic resonance imaging brain
Connections
- Infectious Disease
- Toxoplasma (the Parasite) — the organism itself: biology, life cycle, and how it spreads.
- Toxoplasmosis Symptoms and Diagnosis
- Toxoplasmosis Treatment and Prevention
- Leishmaniasis
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
- Meningitis
- Lyme Disease
- CD4 Count
- Uveitis
- Immune Boosting
- Vitamin D3
- Rocky Mountain Spotted Fever
- Antiparasitic Treatment for Toxoplasmosis
- Ocular Toxoplasmosis — retinochoroiditis, the leading infectious cause of retinitis worldwide.
- Congenital Toxoplasmosis — transmission across the placenta during pregnancy.
- Pregnancy Screening and Prevention — serology timing in pregnancy and how to avoid a first infection.